Significant improvement in overall survival among patients diagnosed with low-risk myelodysplastic syndrome treated with selective serotonin reuptake inhibitors

Br J Haematol. 2017 Apr;177(1):142-144. doi: 10.1111/bjh.14031. Epub 2016 Apr 7.

Authors

Ang Li¹, Sarvari V Yellapragada^{1

2}, Martha Mims^{1

2}, Anna Frolov^{1

2}, Gustavo A Rivero^{1

2}

Affiliations

¹ Section of Hematology/Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
² The Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX, USA.

PMID: 27061100
DOI: 10.1111/bjh.14031

No abstract available

Keywords: cytokine; myelodysplasia; selective serotonin reuptake inhibitor; serotonin..

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Myelodysplastic Syndromes / diagnosis
Myelodysplastic Syndromes / drug therapy*
Myelodysplastic Syndromes / mortality*
Proportional Hazards Models
Selective Serotonin Reuptake Inhibitors / therapeutic use*
Survival Rate
Treatment Outcome

Substances

Serotonin Uptake Inhibitors